Advertisement
ABBV or INSM or REGN
Which Stock Would AI Choose? AbbVie (ABBV) vs. Insmed (INSM) vs. Regeneron (REGN) Stock Comparison
Key Takeaways
- ABBV offers stability with steady recent gains around 2-3% monthly, driven by immunology drugs like Skyrizi and Rinvoq, alongside a low beta of 0.33 and analyst targets near $249.
- INSM leads in momentum with 89-90% one-year returns, fueled by Brinsupri's strong launch exceeding $144M in its first full quarter and 2026 guidance over $1B, though YTD down 17-20% amid volatility.
- REGN shows balanced growth potential with promising obesity drug olatorepatide Phase 3 results, mixed recent performance (YTD flat to slight decline), and undervaluation signals per DCF models suggesting 56% upside.
- Across one-year relative performance, INSM outperforms at ~90%, followed by ABBV (~17-28%) and REGN (~13-18%).
- All three biotech/pharma plays face sector risks like competition and regulatory hurdles, but INSM's high growth contrasts ABBV's dividend stability.
- Market sentiment favors growth catalysts, with INSM and REGN showing pipeline momentum over ABBV's mature portfolio.
Introduction
This stock comparison examines ABBV, INSM, and REGN—three biopharmaceutical leaders in immunology, rare lung diseases, and innovative therapies like oncology and obesity treatments. Traders seeking momentum may eye INSM's surge, while investors favoring stability might prefer ABBV's established revenue streams. REGN appeals to those betting on pipeline breakthroughs. In the current market, with biotech volatility amid economic shifts, this analysis highlights relative performance, growth drivers, and sentiment for informed positioning in stock comparison and market trends.
ABBV Overview and Recent Performance
AbbVie (ABBV), a research-based biopharmaceutical giant headquartered in North Chicago, focuses on immunology, oncology, neuroscience, and aesthetics, with key products like Skyrizi, Rinvoq, Imbruvica, and Botox. Employing ~57,000 people, it generates robust revenue from autoimmune and cancer therapies. In recent market activity, ABBV has shown resilience, posting modest gains of 2-3% monthly and YTD returns around flat to +0.15%, outperforming the S&P 500 in some periods. Influences include positive Phase 1 results for ABBV-295 (obesity analog), a $380M manufacturing expansion for neuroscience/obesity drugs, and analyst targets averaging $249 amid competitive pressures on Skyrizi. Earnings beats and low beta (0.33) support steady sentiment, though high P/E (~96) reflects growth expectations.
INSM Overview and Recent Performance
Insmed (INSM), based in Bridgewater, NJ, specializes in therapies for serious rare diseases, particularly pulmonary conditions, with approved drugs like ARIKAYCE and the newly launched Brinsupri (brensocatib) for non-CF bronchiectasis. With ~1,664 employees, it targets underserved markets via liposomal technology. Recent weeks have seen volatility, with shares pulling back 6-7% monthly and YTD declines of 17-20%, despite a stellar ~90% one-year surge. Key drivers include Brinsupri's "stunning" debut at $144.6M net revenue in its first full quarter (exceeding expectations), full-year 2025 revenue up 67% to $606M, and 2026 guidance of at least $1B for Brinsupri plus ARIKAYCE growth (e.g., 40% in Japan). Analyst targets rose to $211, boosting sentiment amid pipeline advances like TPIP.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN), headquartered in Tarrytown, NY, is a fully integrated biotech firm inventing medicines for eye diseases, cancer, allergic/inflammatory conditions, and metabolic disorders, with flagships like Eylea and Dupixent collaborations. Employing ~15,410, it leverages VelociSuite technologies for rapid development. Recent performance has been mixed, with ~1% monthly gains offset by flat YTD returns (~0.14-0.36%) and 13-18% one-year gains. Positive sentiment stems from promising Phase 3 obesity drug olatorepatide results signaling undervaluation (DCF implies ~57% upside to $1,765/share), regulatory wins, and gene therapy advances. Analyst targets average $873, supporting positioning despite broader biotech pressures.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of over 25 top-performing AI trading bots from its library of hundreds, each scanning thousands of tickers for real-time signals tailored to current market conditions like volatility and sector rotations. These bots vary in styles—trend following, dip buying, hedging—and timeframes from 5min to 60 days, with stats like annualized returns up to +217%, win rates of 53-95%, profit factors to 9.0, and low drawdowns (e.g., $1,576 absolute). Examples include biotech ETF bots at 95% win rates and semiconductor agents at 70-80% wins. Only the most suitable for today’s environment earn a spot, helping traders exploit momentum across growth areas. Explore Trending AI Robots to align bots with your strategy.
Head-to-Head Comparison
ABBV’s diversified business model emphasizes mature immunology/on oncology revenue (~$61B annually) versus INSM’s niche rare disease focus and REGN’s broad pipeline innovation. Growth drivers contrast: INSM’s 67% revenue jump and $1B+ guidance outpace ABBV’s steady immunology expansion and REGN’s obesity/cancer catalysts. Recent momentum favors INSM (90% 1Y) over ABBV (17%) and REGN (14%), but ABBV wins on stability (low beta, dividends). Risks include competition for all, with INSM’s losses/ volatility highest, REGN pipeline-dependent. Valuation sensitivity shows REGN undervalued (P/E 19), ABBV premium (P/E 96), INSM growth-priced. Sentiment tilts to INSM’s launches, REGN’s upside.
Tickeron AI Verdict
Tickeron’s AI currently leans toward INSM for its superior trend consistency, Brinsupri catalysts, and relative outperformance (90% 1Y), positioning it strongly in high-growth biotech niches amid recent market rotations. REGN follows closely on pipeline stability and undervaluation, while ABBV suits lower-risk plays. Observable momentum and revenue guidance suggest higher probability for INSM near-term gains, though volatility warrants caution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileINSM’s FA Score has 1 green FA rating(s), and REGN’s FA Score reflects 1 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- INSM’s FA Score: 1 green, 4 red.
- REGN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while INSM’s TA Score has 5 bullish TA indicator(s), and REGN’s TA Score reflects 2 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 5 bearish.
- INSM’s TA Score: 5 bullish, 5 bearish.
- REGN’s TA Score: 2 bullish, 7 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а -0.43% price change this week, while INSM (@Biotechnology) price change was -4.69% , and REGN (@Biotechnology) price fluctuated -1.70% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
INSM is expected to report earnings on Apr 30, 2026.
REGN is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABBV | INSM | REGN | |
| Capitalization | 368B | 33.4B | 79.2B |
| EBITDA | 17.6B | -1.18B | 5.82B |
| Gain YTD | -8.262 | -11.049 | -2.863 |
| P/E Ratio | 87.74 | N/A | 18.05 |
| Revenue | 61.2B | 606M | 14.3B |
| Total Cash | 5.26B | 1.43B | 8.61B |
| Total Debt | 67.5B | 587M | 2.71B |
ABBV | INSM | REGN | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 67 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 37 Fair valued | 78 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 14 | 33 | 75 | |
SMR RATING 1..100 | 1 | 100 | 53 | |
PRICE GROWTH RATING 1..100 | 58 | 42 | 47 | |
P/E GROWTH RATING 1..100 | 40 | 100 | 36 | |
SEASONALITY SCORE 1..100 | 2 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for ABBV (37) in the Pharmaceuticals Major industry, and is significantly better than the same rating for INSM (78) in the Biotechnology industry. This means that REGN's stock grew somewhat faster than ABBV’s and significantly faster than INSM’s over the last 12 months.
ABBV's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is in the same range as INSM (33) in the Biotechnology industry, and is somewhat better than the same rating for REGN (75) in the Biotechnology industry. This means that ABBV's stock grew similarly to INSM’s and somewhat faster than REGN’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for REGN (53) in the Biotechnology industry, and is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that ABBV's stock grew somewhat faster than REGN’s and significantly faster than INSM’s over the last 12 months.
INSM's Price Growth Rating (42) in the Biotechnology industry is in the same range as REGN (47) in the Biotechnology industry, and is in the same range as ABBV (58) in the Pharmaceuticals Major industry. This means that INSM's stock grew similarly to REGN’s and similarly to ABBV’s over the last 12 months.
REGN's P/E Growth Rating (36) in the Biotechnology industry is in the same range as ABBV (40) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for INSM (100) in the Biotechnology industry. This means that REGN's stock grew similarly to ABBV’s and somewhat faster than INSM’s over the last 12 months.
| ABBV | INSM | REGN | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 37% | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 58% | 1 day ago 76% | 1 day ago 58% |
| Momentum ODDS (%) | 1 day ago 47% | 1 day ago 83% | 1 day ago 46% |
| MACD ODDS (%) | 1 day ago 58% | 1 day ago 83% | 1 day ago 70% |
| TrendWeek ODDS (%) | 1 day ago 47% | 1 day ago 73% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 51% | 1 day ago 74% | 1 day ago 61% |
| Advances ODDS (%) | 3 days ago 57% | 11 days ago 71% | 11 days ago 64% |
| Declines ODDS (%) | 5 days ago 47% | 1 day ago 73% | 1 day ago 51% |
| BollingerBands ODDS (%) | 1 day ago 62% | 1 day ago 73% | 1 day ago 51% |
| Aroon ODDS (%) | 1 day ago 45% | 1 day ago 80% | 1 day ago 71% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JRE | 25.69 | N/A | N/A |
| Janus Henderson US Real Estate ETF | |||
| MVFD | 29.49 | -0.01 | -0.04% |
| Monarch Volume Factor Dividend Tree ETF | |||
| JULP | 31.19 | -0.02 | -0.06% |
| PGIM S&P 500 Buffer 12 ETF - Jul | |||
| UMI | 57.64 | -0.06 | -0.10% |
| USCF Midstream Energy Income ETF | |||
| CGMS | 27.47 | -0.08 | -0.29% |
| Capital Group U.S. Multi-Sector Inc ETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -2.10% | ||
| BMY - ABBV | 58% Loosely correlated | -1.43% | ||
| PFE - ABBV | 57% Loosely correlated | -1.10% | ||
| BIIB - ABBV | 55% Loosely correlated | -2.34% | ||
| AMGN - ABBV | 54% Loosely correlated | -1.29% | ||
| NVS - ABBV | 53% Loosely correlated | -0.65% | ||
More | ||||